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Abstract
Perturbations in lipid metabolism characterize many of the chronic diseases currently plaguing our society, such as
obesity, diabetes, and cardiovascular disease. Thus interventions that target plasma lipid levels remain a primary
goal to manage these diseases. The determinants of plasma lipid levels are multi-factorial, consisting of both
genetic and lifestyle components. Recent evidence indicates that fatty acid desaturases have an important role in
defining plasma and tissue lipid profiles. This review will highlight the current state-of-knowledge regarding three
desaturases (Scd-1, Fads1 and Fads2) and their potential roles in disease onset and development. Although research
in rodent models has provided invaluable insight into the regulation and functions of these desaturases, the extent
to which murine research can be translated to humans remains unclear. Evidence emerging from human-based
research demonstrates that genetic variation in human desaturase genes affects enzyme activity and, consequently,
disease risk factors. Moreover, this genetic variation may have a trans-generational effect via breastfeeding. There-
fore inter-individual variation in desaturase function is attributed to both genetic and lifestyle components. As
such, population-based research regarding the role of desaturases on disease risk is challenged by this complex
gene-lifestyle paradigm. Unravelling the contribution of each component is paramount for understanding the inter-
individual variation that exists in plasma lipid profiles, and will provide crucial information to develop personalized
strategies to improve health management.
Introduction
Perturbations in lipid metabolism characterize many of
the chronic diseases currently plaguing our society, such
as obesity, type 2 diabetes, and cardiovascular disease
[1-3]. Lipids constitute a fundamentally important group
of diverse metabolites, with critical structural and func-
tional roles within the biological organism. More specifi-
cally, many lipid species have been shown to have key
roles in such diverse biological processes as signal trans-
duction, membrane trafficking and sorting, morphogen-
esis, and proliferation [4-6]. While it remains unclear
whether perturbations in lipid metabolism are the cause
or simply a downstream effect in the development of
chronic disease, modifying lipid levels by medical and/or
lifestyle interventions remains a primary goal for health
management.
Lifestyle factors are typically deemed modifiable risk
factors in the development of disease and include high
body mass index (BMI), physical inactivity, smoking,
alcohol use, and unhealthy eating habits [7-10]. While
the authors recognize that each of these lifestyle factors
plays an important role in the development of chronic
diseases, there is a growing recognition and appreciation
of the relationship between diet and health. Indeed the
links between the amount and type of dietary fats con-
sumed, and various disease states, are evident in popula-
tion-based observational studies [11-14]. These studies
have associated diets high in saturated fats, refined
sugars and high-fat dairy products with a higher inci-
dence of atherosclerosis, cardiovascular disease, meta-
bolic syndrome, cancer and autoimmune diseases. This
diet, typically referred to as the Western diet, is com-
monly associated with a distinct dietary fat composition
enriched in saturated fats (SFAs) and n-6 polyunsatu-
rated fatty acids (PUFAs), and poor in n-3 PUFA
[15,16]. In contrast a Mediterranean diet emphasizes the
consumption of fruits, vegetables, whole grains, wine
and poultry, leading to higher intakes of fatty acids such
as n-3 PUFAs and monounsaturated fatty acids
(MUFAs) [14,17]. These fatty acids are routinely
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any medium, provided the original work is properly cited.associated with decreased risks for coronary artery dis-
ease, hypertension, diabetes, arthritis, inflammatory, and
autoimmune diseases [3,8].
Although poor dietary habits can be detrimental to
health by themselves, the numerous interactions between
nutrients and genes can further modulate an individual’s
risk for developing disease [18]. The determinants of
plasma lipids are multi-factorial; however, it remains
unclear to what extent genetic variability contributes to
the inter-individual differences observed in plasma lipid
profiles. Identifying those gene variants that can modu-
late lipid levels is crucial for our understanding of the
development and severity of disease. While the molecular
pathways underlying lipid metabolism are both numerous
and complex, fatty acid desaturases have been shown to
play a key role in determining both plasma and tissue
fatty acid profiles. Moreover, emerging evidence demon-
strates that variation in fatty acid desaturase genes can
modify whole-body lipid metabolism.
The aim of this review is to highlight the current
state-of-knowledge regarding three fatty acid desa-
turases: stearoyl CoA desaturase 1 (Scd-1), fatty acid
desaturase 1 (Fads1), and fatty acid desaturase 2
(Fads2). We will also discuss human studies that have
begun to explore the genetic contribution underlying
the inter-individual variability that exists with regards to
desaturase activity. This review will demonstrate that
fatty acid desaturases represent an important point of
consideration for research aimed at preventing and
treating various diseases through personalized dietary
interventions.
Stearoyl Coenzyme Desaturase-1: Background
Stearoyl Coenzyme Desaturase-1 (SCD-1) is the enzyme
that catalyses the endogenous biosynthesis of MUFAs
(i.e. palmitoleic acid, C16:1n-7; oleic acid, C18:1n-9)
from de novo synthesized or dietary saturated fatty acids
(SFA, i.e. palmitic acid, C16:0; stearic acid, C18:0)
[19,20]. Moreover, SCD-1 has a specific affinity for two
of the most abundant saturated fatty acids found in diet:
palmitic and stearic acids. Palmitic acid is the major
lipid in palm tree oils; however, it can also be found in
other vegetable and animal sources. Stearic acid is found
predominantly in fats and oils from animals and vegeta-
bles, and is usually consumed in meats, cocoa and pro-
cessed shortening, spreads and baked products. The
increased consumption of SFA-enriched foods charac-
terizes Western dietary habits and is associated with the
dramatic increases in cardiovascular disease and obesity
[13,14]. As the rate-limiting enzyme responsible for cat-
alyzing the conversion of SFAs into MUFAs, SCD-1 has
become an interesting target in an attempt to under-
stand the onset and development of the aforementioned
diseases.
Rodent Scd-1 knockout models have been invaluable
for advancing our understanding of SCD-1 function and
regulation. While the goal of this review is not to pro-
vide a comprehensive description of SCD-1 biochemis-
try, it is nevertheless important to provide a brief
overview of the current state-of-knowledge regarding
this enzyme in order to appreciate the recent progress
made in human-based research. A thorough overview of
SCD-1 biochemistry can be obtained in reviews by
Ntambi and colleagues [21,22]. Recent findings suggest
that SCD-1 activity is tightly regulated, and that this
regulation is disrupted in various disease states; how-
ever, it remains unclear whether perturbations in SCD-1
activity cause disease or are simply a response to dis-
ease. Furthermore, it appears that the degree of SCD-1
activity may underlie different health outcomes. Studies
using Scd-1 knockout models revealed that an increase
in SCD-1 activity is tightly associated with an obese
phenotype, while a decrease in SCD-1 activity favours
the development of cardiovascular complications due to
a build-up of SFAs [23,24]. Whether alterations in SCD-
1 activity induce these diseases is unknown; however,
these associations are not isolated cases. Indeed, other
disease states such as insulin resistance, metabolic syn-
drome, and cancer are also characterized by distur-
bances in SCD-1 activity [21,25-28]. These findings
reinforce that SCD-1 is a critical player in the regulation
of whole-body metabolism and is a promising target for
therapeutic interventions [29].
To study the role of SCD-1, researchers have used
rodents with either a naturally occurring Scd-1 deletion
(asebia strain) or transgenic Scd-1 deletions. A lack of
Scd-1 caused significant decreases in tissue triglycerides
(TG), cholesterol esters (CE), wax esters, and diacylgly-
c e r o l s( D A G ) ,a sw e l la sar e d u c t i o ni nl i p i ds y n t h e s i s
and an increase in b-oxidation, thermogenesis and insu-
lin sensitivity, in the liver, muscle, and brown adipose
tissue [19,20]. The resulting decrease in SCD-1 activity
also led to a reduced desaturation index (i.e. the ratio of
18:1/18:0 and 16:1/16:0) [23,30]. Furthermore, Scd-1
deficient mice were found to be resistant to diet-induced
obesity and characterized by decreased body weight,
improved insulin sensitivity, and decreased hepatic stea-
tosis [31,32].
While such data suggests a decrease in SCD-1 activity
may be beneficial for weight management, emerging
research indicates this reduction may also contribute to
atherosclerosis; thus reinforcing that maintaining a bal-
ance in SCD-1 activity is paramount to optimize health.
In 2008, MacDonald et al. studied the effect of Scd-1
deficiency on atherosclerosis in a hyperlipidemic, low-
density lipoprotein receptor (LDLR)-deficient mouse
model fed a Western diet [24]. LDLR-/- control mice
developed diet-induced diabetes and obesity in the short
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was additionally disrupted in a group of LDLR-/- mice,
these animals exhibited lower body weights but
increases in atherosclerotic lesion areas at the aortic
root and plasma inflammatory markers (IL-6, ICAM-1,
IL-1b and IL-12p70) [24]. This suggests that the ability
of SCD-1 to metabolize an increased intake of dietary
SFA is critical in order to prevent atherosclerosis.
Further confirming the importance of balanced SCD-1
activity, Fessler et al. analyzed the influence of SCD-1
on inflammatory pathways by studying the associations
between SFA, n-3 PUFAs, and toll-like receptor 4
(TLR4) - an activator of the innate immune system [33].
The authors demonstrated that the accumulation of
SFA following Scd-1 deletion promoted the development
of inflammation and disease via TLR4-mediated signal-
ling pathways. Taken together, Scd-1 appears to play an
important role in maintaining a balance in lipid profiles
that, when deregulated, can contribute to inflammation,
atherosclerosis, hypertriglyceridemia, and metabolic syn-
drome. While rodent research provides fundamental
information regarding mechanism of action, the extent
to which this knowledge can be translated to humans is
still unknown.
Interactions between diet and SCD-1
Few human intervention studies exploring the dietary
regulation of SCD-1 are available to date. In 2002, Attie
et al. analyzed the associations between diet, plasma TG,
and SCD-1 activity in 429 healthy, Caucasian adults
[23]. Participants were placed on a low-fat/high-carbo-
hydrate diet (61-65% energy from carbohydrates) for 4-6
weeks. Changes in plasma lipids and lipoproteins levels
were examined following the short-term intervention.
This study revealed that before the dietary intervention,
the C18:1/C18:0 desaturation ratio, an in vivo measure
of SCD-1 activity, accounted for 11% of the variation in
plasma triglyceride concentrations. However, after the
consumption of a diet enriched in carbohydrates, the
desaturation ratio accounted for over 40% of the varia-
tion in individuals whose triglyceride levels increased
after the intervention. This suggests that SCD-1 may
play a role in mediating carbohydrate-induced lipemia;
therefore future research that analyzes SCD-1 activity
within this context is warranted.
In 2004, Shiwaku et al. also analyzed the relationship
between the 18:1/18:0 desaturation ratio and triglyceride
levels [34]; however, the authors additionally explored
the impact of ethnicity and dietary habits, assessed by
the levels of plasma n-3 PUFA, on this relationship. The
study recruited participants from three distinct ethnic
groups: Japanese (n = 411), Korean (n = 418), and Mon-
golian (n = 251). Japanese participants consumed more
fish than Koreans, who in turn consumed more than
Mongolians. They found that fish consumption was
positively correlated with plasma levels of n-3 PUFA. In
line with the previously mentioned study by Attie and
colleagues, significant associations were observed
between the SCD-1 desaturation ratio (18:1/18:0) and
plasma triglyceride levels in Japanese and Mongolians
groups. Interestingly, this association was non-significant
in the Korean group, suggesting ethnic differences.
While Japanese and Koreans consume similar quantities
of fish, differences in the degree to which SCD-1 activity
affected triglyceride levels were observed; further rein-
forcing potential ethnic-specific factors that regulate
plasma triglyceride levels above and beyond the influ-
ence of diet. When comparing the three ethnicities, the
authors reported that the 18:1/18:0 desaturation ratio,
n-3 PUFAs, age, gender, BMI, insulin resistance, and
free fatty acids accounted for more than 50% of the var-
iance in plasma triglyceride levels in Japanese and Mon-
golians individuals. In contrast, these same factors
accounted for only 28% of plasma triglyceride varition
in Koreans. Furthermore, hypertriglyceridemia was cor-
related with an increase in SCD-1 activity and decrease
in plasma n-3 PUFA in an ethnic-specific manner. In
Mongolian participants however, triglyceride levels were
reduced independent of their low plasma n-3 PUFA
concentrations, which the authors attributed to their
low fish consumption. These findings suggest that
SCD-1 activity is sensitive to diet and, more importantly,
varies according to the genotype of distinct ethnic popu-
lations. Future nutrigenomic research should consider
integrating the analysis of ethnic-specific variation in the
Scd-1 gene, SCD-1 activity, and dietary habits in order
to further clarify the role of this desaturase on clinical
parameters commonly associated with metabolic dis-
eases such as obesity and diabetes.
Genetic Variation in Scd-1 and its Impact on
Human Disease
Initial studies in subjects with familial combined hyperli-
pidemia (FCHL) revealed that this genetic condition is
characterized by alterations in the lipid profile that may
be explained in part by changes in SCD-1 activity
[23,35]. While it does not appear that Scd-1 variants
are responsible for FCHL, this does not preclude
the notion that genetic variation in Scd-1 may affect
enzyme activity and, subsequently, contribute to disease
development.
Indeed, evidence suggests that genetic variation in
Scd-1 may be associated with metabolic and physical
parameters characterizing various disease states [36].
Furthermore, genetic studies suggest that these associa-
tions may be due to the effect of Scd-1 gene variants on
SCD-1 activity, which consequently modifies plasma
lipid profiles. Taken together, this reinforces the
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tion in Scd-1 on disease, especially when its interaction
with dietary nutrients may modify disease development.
T h ef i r s ts t u d ye x a m i n i n gg e n e t i cv a r i a t i o ni nScd-1
and its impact on disease was published in 2004 [37].
Liew et al. analyzed the association between Scd-1 poly-
morphisms and susceptibility to type 2 diabetes in 608
diabetic and 600 control subjects of Irish and British
descent. Despite the relatively small sample size used in
this study, a borderline association was observed
between the rs41290540 single nucleotide polymorphism
(SNP) and diabetes risk (p = 0.059), in which the fre-
quency of the minor allele was higher in the diabetic
group [37]. However, this promising association was not
replicated in an independent follow-up study performed
by the same authors. While the lack of reproducibility is
of concern, the results do not exclude the possibility
that the minor allele for this Scd-1 SNP affects particu-
lar traits related to type 2 diabetes [37]. As such, future
studies in larger cohorts may clarify the association
between the rs41290540 SNP and diabetes risk. In 2007,
Warensjo et al. analyzed the association between Scd-1
polymorphisms, SCD-1 activity, obesity, and insulin sen-
sitivity in a population of 1143 elderly Swedish men
[36]. They reported that the minor alleles of four Scd-1
SNPs (rs10883463, rs7849, rs2167444 and rs508384)
were associated with a lower BMI, smaller waist circum-
ference, and improved insulin sensitivity. For instance,
the minor allele for rs7849 was correlated with a 23%
increase in insulin sensitivity and 4 cm decrease in waist
circumference. In many aspects, the phenotype asso-
ciated with these minor alleles reflected the metabolic
changes seen in Scd-1 deficient mice. Consequentially,
the authors hypothesized that these minor alleles led to
decreased SCD-1 activity; however, no significant change
in SCD-1 activity was observed in individuals with these
alleles. While it remains possible this is related to the
relatively small cohort, it is more likely that measuring
desaturation ratios in plasma fails to accurately repre-
sent long term or tissue-specific changes in SCD-1
activity [36].
Fatty acid Desaturases: Background
The delta-6 desaturase (D6D) and delta-5 desaturase
(D5D) are membrane-bound enzymes that catalyze the
rate-limiting formation of long-chain PUFA [38,39].
These two enzymes are encoded by the fatty acid desa-
turase 2 (Fads2)a n d1( Fads1) genes, respectively. The
Fads1 and Fads2 genes are found in a head-to-head
fashion in a cluster on human chromosome 11 (11q12-
q13.1), separated by an 11 kb region [38,40]. A third
fatty acid desaturase gene (Fads3) also lies in the Fads
cluster; however, the function of its translated product
remains unknown [41]. Since all three Fads genes have
12 exons, 11 introns and share a common location in
chromosome 11, it is believed that they arose evolutio-
narily from gene duplication and acquired substrate spe-
cificity over time [38].
D6D catalyzes the conversion of a-linolenic acid
(ALA, 18:3n-3) and linoleic acid (LA, 18:2n-6) into
stearidonic acid (STD, 18:4n-3) and g-linolenic acid
(GLA, 18:3n-6), respectively (Figure 1). This is followed
by an elongation step, after which D5D introduces a
double bond at the Δ5 position in a 20-carbon fatty acid
chain. D5D catalyzes the conversion of eicosatetraenoic
acid (ETA, 20:4n-3) and dihomo-g-linolenic acid
(DGLA, 20:3n-6) into eicosapentaenoic acid (EPA,
20:5n-3) and arachidonic acid (AA, 20:4n-6), respectively
[38,39] (Figure 1). The aforementioned PUFAs have
important roles in maintaining membrane integrity and
regulating cellular signaling events [5]. Irregularities in
membrane fatty acid composition have been associated
Figure 1 Fatty acid desaturases in PUFA and eicosanoid biosynthesis.T h eD 6 D( Fads2)a n dD 5 D( Fads1) enzymes play important roles in
the biosynthesis of polyunsaturated fatty acids (PUFA). Moreover, these desaturases lead to the generation of pro-inflammatory (via n-6 PUFA)
and anti-inflammatory (via n-3 PUFA) eicosanoids.
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[42,43], atopic eczema [44], autoimmune diseases [2],
cancer [45], and coronary heart diseases [3,46,47].
Furthermore, D6D and D5D activity is also known to
regulate the levels of pro-inflammatory and anti-inflam-
matory eicosanoids derived from PUFAs [48]. The pro-
inflammatory eicosanoids derived from AA are now
known to contribute to the development of allergies
[2,49], cardiovascular disease [50,51], and cancer [52].
Despite the wide-spread implications for Fads in the
development of disease, only a few studies have directly
studied the regulation of fatty acid desaturases in
human tissue [53]. As such, the use of rodent models
has provided important insight regarding the roles of
these enzymes on lipid metabolism and disease.
The inhibition of D5D and D6D in an edema rodent
model demonstrated that a marked decrease in inflam-
mation was correlated with decreased levels of AA in
liver, plasma and peritoneal cells [54]. Moreover, the
inhibition of D6D was correlated with decreases in
edema. These results strongly agree with other rodent
studies which demonstrated that decreased levels of AA
reduced the eicosanoid pool and attenuated AA-
mediated signalling pathways regulating inflammatory
responses [50,55]. In 2002, Hansen-Petrik et al. used
two in vivo models of colorectal carcinogenesis (Apc
Min/
1 mice and nude mice injected with HT-29 colonocytes)
to examine the role of D6D on colon cancer [52]. As
observed in other studies, the inhibition of D6D led to
decreases in AA and an accumulation of its precursor
LA. Furthermore, D6D inhibition reduced the number
of tumours by 36-37% and decreased primary tumour
size by 35%. When AA was directly supplemented, the
effects of the D6D inhibitor on fatty acid composition
and tumourigenesis in mice were abrogated. These
results reinforce the importance of D6D activity in
maintaining AA levels to regulate the production of
inflammatory signalling molecules. Therefore, studying
the extent by which genetic variation and dietary habits
influence the regulation of D6D and D5D activity may
lead to a better understanding of how these factors
mediate the susceptibility to various diseases.
The Role of Genetic Variation in Fads1 and Fads2
in humans
Emerging research has demonstrated that genetic varia-
tion in Fads1 and Fads2 are associated with alterations
in fatty acid composition that may subsequently modify
an individual’s propensity for disease. Although such
research has only recently begun, significant associations
have already been identified between Fads polymorph-
isms and fatty acid levels, which are summarized in
Table 1.
In 2006, Schaeffer et al. analyzed the associations
between genetic variants in human Fads1 and Fads2,
and fatty acid composition in serum phospholipids [49].
Eighteen SNPs located in the Fads cluster were analyzed
in a cohort of 727 Caucasian adults from Germany. The
authors identified several SNPs, as well as statistically
reconstructed haplotypes in the Fads cluster, that were
strongly associated with changes in phospholipid fatty
acid composition. For the most affected fatty acid, AA,
up to 28% of its variance could be explained by the
SNPs in the studied cluster, followed by its precursors
eicosadienoic acid (EDA, C20:2 n-6) at 12% and DGLA
at 10%. It was observed that subjects carrying various
minor alleles had higher levels of LA and ALA, and
decreased levels of AA and EPA in serum phospholipids.
Furthermore, a haplotype analysis reinforced that car-
riers of minor alleles had increased levels of ALA and
LA, and decreased levels of AA and EPA. The authors
suggested that individuals with these minor alleles may
have a lower prevalence for immunological diseases,
such as allergic rhinitis and atopic eczema due to the
significantly lower concentrations of AA observed; how-
ever, this remains to be demonstrated fully by future
research since significance was lost after correcting for
multiple testing.
A subsequent study verified these associations in an
independent cohort composed of 535 participants from
the Bavarian Nutrition Survey II (BVS-II) [56]. Rzehak
and colleagues conducted a haplotype analysis on fatty
acid composition in both serum phospholipid and red
blood cell (RBC) membranes. The results confirmed
that minor allele haplotypes were strongly linked to
changes in fatty acid composition, such as decreased AA
level in circulating serum phospholipids. Furthermore,
minor allele haplotypes were found to influence fatty
acid composition at a cellular level, which was repre-
sented by fatty acid alterations in the RBC membrane.
Two other studies have assessed fatty acid composi-
tion in both serum phospholipids and RBC membranes
with the purpose of measuring short-term transient
alterations and long-term chronic modifications in fatty
acid status, respectively. Malerba and colleagues exam-
ined the association between Fads gene variants and
fatty acid composition in 658 cardiovascular disease
patients recruited in the Verona Heart Project [57]. This
study revealed that homozygote and heterozygote car-
riers of various minor alleles had a fatty acid profile
characterized by significantly lower levels of AA in both
serum phospholipids and erythrocyte membranes, as
found independently in two other studies [49,56]. After
multiple test adjustments, significance diminished, and
the only significant association that remained was that
of a constructed haplotype within the Fads cluster and
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dbSNP ID Gene, Region Allele
(M/
m)
Population Size &
Ethnicity
Association findings Ref
Fads1
rs174537 Fads1 intron G/T n = 1453, Caucasian
(ITA)
n = 1120, Caucasian
(USA)
GG < GT&TT: ↑LA, ALA; ↓EDA, AA, EPA, LDL-C & total
cholesterol in serum
[61]
rs174544 Fads1 3’ UTR C/A n = 727, Caucasian
(GER)
CC < CA < AA: ↑LA, EDA, DGLA & ALA; ↓GLA, AA, DTA, EPA &
DPA in serum
[49]
rs174546 Fads1 3’ UTR C/T n = 1144, Caucasian
(EUR)
CC < CT < TT: ↑LA, DGLA, ALA; ↓AA, EPA, DHA in serum
CC < CT&TT: ↓GLA in serum
[60]
rs174545 Fads1 3’ UTR C/G n = 876, Caucasian
(ITA)
CC < CG < GG: ↑AA, AA/LA, EPA/ALA; ↓LA, ALA in RBC [51]
n = 658, Caucasian
(ITA)
CC < CG < GG: ↑AA; ↓ALA, EDA in serum and RBC [57]
rs174547 Fads1 intron T/C n = 1809, Caucasian
(GER)
TT < TC < CC: ↑PC aa C36:3/PC aa C36:4 [65]
n = 422, Caucasian
(UK)
TT < TC < CC: ↑PC aa C36:3/PC aa C36:4 [65]
rs174553 Fads1 intron A/G n = 727, Caucasian
(GER)
AA < AG < GG: ↑LA, EDA, DGLA & ALA; ↓GLA, AA, DTA, EPA &
DPA in serum
[49]
n = 69, 74%
Caucasian (CAN)
AA < AG&GG: ↑LA; ↓AA in plasma and RBC during gestation [68]
n = 54, 74%
Caucasian (CAN)
AA < AG < GG: ↑EDA; ↓AA, EPA, DPA in breast milk [68]
rs174556 Fads1 intron C/T n = 727, Caucasian
(GER)
CC < CT < TT: ↑LA, EDA, DGLA & ALA in serum; ↓GLA, AA, DTA,
EPA & DPA in serum
[49]
n = 658, Caucasian
(ITA)
CC < CT < TT: ↑EDA in serum & RBC; ↓AA in serum & RBC [57]
rs174561 Fads1 intron CpG-island, promoter
region
T/C n = 727, Caucasian
(GER)
TT < TC < CC: ↑LA, EDA, DGLA, ALA in serum; ↓GLA, AA, DTA,
EPA & DPA in serum
[49]
n = 658, Caucasian
(ITA)
TT < TC < CC: ↑EDA in serum & RBC; ↓AA in serum & RBC [57]
n = 309, Caucasian
(DUT)
TT < TC < CC: ↑GA, EA LA, EDA, DGLA; ↓GLA, AA, DTA, DHA in
plasma phospholipids
TT < TC < CC: ↑DGLA; ↓AA, DTA, EPA, DHA in breast milk
[67]
Fads2
rs174570 Fads2 intron C/T n = 727, Caucasian
(GER)
CC < CT&TT: ↑EDA in serum; ↓GLA, AA, DTA in serum [49]
n = 876, Caucasian
(ITA)
CC < CT < TT: ↑LA, ALA in RBC; ↓AA, AA/LA in RBC [51]
n = 658, Caucasian
(ITA)
CC < CT < TT: ↑LA in RBC, ↓AA in serum & RBC [57]
n = 1144, Caucasian
(EUR)
CC < CT < TT: ↑LA, ALA; ↓AA in serum
CC < CT&TT: ↓GLA in serum
[60]
rs174572 Fads2 intron C/T n = 1144, Caucasian
(EUR)
CC < CT < TT: ↑LA, DGLA, ALA; ↓AA, EPA in serum
CC < CT&TT: ↓GLA, DHA in serum
[60]
rs174575 Fads2 intron C/G n = 54, 74%
Caucasian (CAN)
CC < CG&GG: ↓AA, EPA, DPA & DHA in breast milk [68]
n = 309, Caucasian
(DUT)
CC < CG < GG: ↑GA, LA, EDA, DGLA; ↓AA, DTA, DHA in plasma
phospholipids
CC < CG < GG: ↑DGLA; ↓PEA, AA, DTA, EPA, DPA in breast milk
[67]
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rs174583 Fads2 intron C/T n = 727, Caucasian
(GER)
CC < CT < TT: ↑LA, EDA, DGLA & ALA in serum; ↓GLA, AA, DTA,
EPA & DPA in serum
[49]
n = 876, Caucasian
(ITA)
CC < CT < TT: ↑LA, ALA in RBC; ↓AA, AA/LA, EPA/ALA in RBC [51]
n = 658, Caucasian
(ITA)
CC < CT < TT: ↑ALA, EDA, LA in serum & RBC; ↓AA in serum &
RBC
[57]
rs174589 Fads2 exon/intron boundary G/C n = 727, Caucasian
(GER)
GG < GC < CC: ↑LA, EDA & DGLA in serum; ↓GLA, AA, EPA &
DPA in serum
[49]
n = 876, Caucasian
(ITA)
GG < GC&CC: ↑AA, AA/LA in RBC; ↓LA, EPA/ALA in RBC [51]
n = 658, Caucasian
(ITA)
GG < GC < CC: ↑AA, in serum & RBC, ↓EDA in serum [57]
n = 1144, Caucasian
(EUR)
GG < GC < CC: ↑LA, DGLA, ALA; ↓AA, EPA in serum
GG < GC&CC: ↓GLA in serum
[60]
rs174602 Fads2 exon/intron boundary A/G n = 727, Caucasian
(GER)
AA < AG < GG: ↑LA, EDA in serum; ↓AA in serum [49]
n = 1144, Caucasian
(EUR)
AA < AG < GG: ↑LA, ALA; ↓AA, EPA in serum [60]
rs174611 Fads2 intron T/C n = 876, Caucasian
(ITA)
TT < TC < CC: ↑LA, ALA in RBC; ↓AA, AA/LA, EPA/ALA in RBC [51]
n = 658, Caucasian
(ITA)
TT < TC < CC: ↑EDA in serum ↓AA in serum & RBC [57]
n = 1144, Caucasian
(EUR)
TT < TC < CC: ↑LA, DGLA, ALA; ↓AA in serum
TT < TC&CC: ↓GLA, EPA in serum
[60]
rs174616 Fads2 intron G/A n = 1144, Caucasian
(EUR)
GG < GA < AA: ↑LA, DGLA; ↓AA in serum
GG < GA&AA: ↑ALA; ↓EPA, DHA in serum
[60]
rs174620 Fads2 intron T/C n = 727, Caucasian
(GER)
TT < TC < CC: ↑DGLA in serum; ↓AA in serum [49]
rs2072114 Fads2 exon/
intron boundary
A/G n = 727, Caucasian
(GER)
AA < AG&GG: ↑ LA, EDA in serum; ↓GLA, AA, DTA in serum [49]
n = 1144, Caucasian
(EUR)
AA < AG < GG: ↑LA, DGLA, ALA; ↓AA in serum
AA < AG&GG: ↓GLA in serum
[60]
rs2524299 Fads2 intron A/T n = 876, Caucasian
(ITA)
AA < AT < TT: ↑LA in RBC; ↓AA, AA/LA in RBC [51]
n = 658, Caucasian
(ITA)
AA < AT < TT: ↓AA in serum and RBC [57]
rs482548 Fads2 3’ UTR C/T n = 727, Caucasian
(GER)
CC < CT&TT: ↑AA, DTA in serum [49]
rs498793 Fads2 intron G/A n = 658, Caucasian
(ITA)
No significant association found with lipid species in serum or
RBC
[57]
n = 1144, Caucasian
(EUR)
GG < GA < AA: ↑AA; ↓LA in serum
GG < GA&AA: ↑EPA in serum
[60]
rs526126 Fads2 exon/
intron boundary
G/C n = 727, Caucasian
(GER)
GG < GC < CC: ↑DGLA in serum [49]
n = 1144, Caucasian
(EUR)
GG < GC < CC: ↑LA, ALA; ↓AA in serum [60]
rs968567 Fads2 5’UTR C/T n = 1144, Caucasian
(EUR)
CC < CT < TT: ↑LA, DGLA, ALA; ↓AA, EPA
CC < CT&TT: ↓GLA in serum
[60]
rs99780 Fads2 intron C/T n = 727, Caucasian
(GER)
CC < CT < TT: ↑levels of LA, EDA, DGLA, ALA in serum; ↓GLA,
AA, EPA, DPA in serum
[49]
Intergenic
rs174627 Fads2/Fads3 Intergenic C/T n = 876, Caucasian
(ITA)
CC < CT < TT: ↑LA, ALA in RBC; ↓AA, AA/LA, EPA/ALA in RBC [51]
n = 658, Caucasian
(ITA)
CC < CT < TT: ↑EDA, AA in serum [57]
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Page 7 of 14the levels of AA in serum and RBC membranes [57].
Martinelli et al. examined the same SNPs used in the
previous study; however, they included an association
analysis between Fads gene variants and coronary artery
disease (CAD), as well as desaturase activity in the RBC
membranes of 610 CAD and 266 CAD-free subjects
from the Verona Heart Project [51]. Almost all SNPs
studied in the Fads cluster were associated with the
desaturation ratios for AA/LA and EPA/ALA, but no
single variant was significantly associated with CAD or
CAD-free subjects. However, haplotypes with a greater
number of risk alleles were more frequent in CAD
patients than CAD-free individuals, as well as being
associated with a higher desaturation ratio (AA/LA),
and increases in high sensitivity C-reactive protein (hs-
CRP), a common inflammatory marker. Regression ana-
lyses adjusted for multiple testing revealed that the AA/
LA ratio is indeed a significant predictor of CAD. The
authors concluded that individual Fads1 and Fads2
polymorphisms had little to no effect on CAD risk; how-
ever, an additive model of risk alleles, which corre-
sponds to a higher desaturase activity, was more
frequent in CAD subjects and showed a significant effect
on CAD susceptibility [51].
Additional studies have explored the relationship
between diet and Fads, and the influence on cardiovas-
cular disease. In 2007, Baylin et al. analyzed the effect of
a common deletion variant in the Fads2 promoter
(rs3834458) on ALA concentrations in adipose tissue
and the risk of nonfatal myocardial infarction (MI) in a
Costa Rican population of men and women diagnosed
as survivors of a first acute MI [58]. The authors
reported that the heterozygous deletion variant of the
Fads2 promoter was prevalent in almost half of the
population (48%) and was associated with a decrease in
serum EPA, GLA, and AA and an increase in eicosatrie-
noic acid (ETE, C20:3 n-3) and EDA, as well as TG,
with increasing number of copies of the variant allele.
However, this deletion was not significantly associated
with MI, nor did it attenuate the association between
ALA in adipose tissue and MI [58]. In contrast with the
author’s original hypothesis, reduced activity of D6D did
not translate into decreased protection from MI as a
result of reduced conversion of ALA into its very-long-
chain products. However, Baylin et al. suggested that
the results of this study may have been masked by the
high availability of dietary ALA compensating for the
defective transcription of D6D in individuals with the
deletion variant. This research involving the Fads2 pro-
moter SNP (rs3834458) w a sf o l l o w e du pb yT r u o n ge t
al., who studied the effect of genetic variation in the
Fads2 SNP on the association between ALA and the
prevalence of the metabolic syndrome. The studied
cohort consisted of 656 metabolic syndrome subjects
and 1159 metabolic syndrome-free subjects from a
Costa Rican population-based case-control study exam-
ining heart disease [59]. A significant trend was
observed for a lower prevalence ratio (PR) of metabolic
syndrome in individuals with high concentrations of adi-
pose tissue ALA, compared to individuals with low
Table 1 Summary of SNP-trait associations identified for Fads1 and Fads2 (Continued)
rs17831757 Fads2/Fads3
Intergenic
T/C n = 658, Caucasian
(ITA)
TT < TC&CC: ↓AA in serum [57]
rs3834458 Fads1/Fads2
intergenic, CpG-island
T/
del*
n = 727, Caucasian
(GER)
TT < T/del < del/del: ↑LA, EDA, DGLA, ALA in serum; ↓GLA, AA,
DTA, EPA, DPA in serum
[49]
n = 1694 (case),
Caucasian (ITAL)
TT < T/del < del/del: ↑ETE & EDA in adipose tissue; ↑ plasma
TG;
↓EPA, GLA & AA in adipose tissue
[58]
n = 876, Caucasian
(ITA)
TT < T/del & del/del: ↑LA, ALA; ↓AA, AA/LA, EPA/ALA in RBC [51]
n = 658, Caucasian
(ITA)
TT < T/del < del/del: ↑ALA, EDA in serum; ↑LA, EDA in RBC;
↓AA in serum and RBC
[57]
n = 309, Caucasian
(DUT)
TT < T/del < del/del: ↑GA, EA, LA, EDA, DGLA; ↓GLA, AA, DTA,
DHA in plasma phospholipids
TT < T/del < del/del: ↑LA, DGLA; ↓AA, DTA, EPA, DPA, DHA in
breast milk
[67]
rs968567 Fads1/Fads2 intergenic, CpG-island,
promoter region
G/A n = 727, Caucasian
(GER)
GG < GA&AA: ↑LA, DGLA in serum; ↓GLA, AA, EPA & DPA in
serum
[49]
Several SNPs have been examined in Fads1 and Fads2; however, only significant associations (p < 0.05) are listed in this table. Associations between Fads genes
and several fatty acids have been identified, including: palmitelaidic acid (PEA, C16:1n-7), gadoleic acid (GA, C20:1n-9), erucic acid (EA, C22:1n-9), linoleic acid (LA,
C18:2n-6), g-linoleic acid (GLA, C18:3n-6), eicosadienoic acid (EDA, C20:2n-6), dihomo-g-linolenic acid (DGLA, C20:3n-6), arachidonic acid (AA, C20:4n-6), adrenic
acid (DTA, C22:4n-6), a-linolenic acid (ALA, C18:3n-3), eicosatrienoic acid (ETE, 20:3n-3), eicosapentaenoic acid (EPA, C20:5n-3), docosapentaenoic acid (DPA,
C22:5n-3), docosahexaenoic acid (DHA, C22:6n-3), phosphatidylcholine diacyl C36:3 (PC aa C36:3), and phosphatidylcholine diacyl C36:4 (PC aa C36:4). Other
abbreviations: LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; RBC, red blood cell; M/m, major and minor allele; and *del, deletion.A↑ indicates an
increase and a ↓ represents a decrease.
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Page 8 of 14adipose tissue ALA. Moreover, a lower PR was asso-
ciated with higher levels of adipose tissue ALA in homo-
zygote and heterozygote carriers of the common T-
allele. This trend, however, lost significance in homozy-
gote carriers of the deletion allele with high levels of
adipose tissue ALA. This suggests that in individuals
with the Fads2 deletion allele, the high consumption of
ALA may only have an attenuated beneficial effect on
the prevalence of the metabolic syndrome, which
demonstrates the influence of genetic variation in Fads2
on the mediation of disease risk. Nevertheless, the
extent to which genetics mediates the association
between diet and disease needs to be explored in further
studies.
Most association studies to date have focused on ana-
lyzing the influence of genetic variation in the Fads
cluster in adult subjects; however, analyzing this influ-
ence in younger subjects provides an alternate perspec-
tive for understanding how genetic variation affects lipid
metabolism. Adolescents have been exposed to fewer
environmental challenges than adults, thus the influence
of the genetic makeup on the inter-individual pheno-
typic variability is more direct in an adolescent cohort.
Bokor et al. recently examined the relationship between
Fads SNPs, plasma fatty acids, TGs and desaturase
activity in a cohort of European adolescents [60]. The
results revealed similar links to those found in adults, in
that significant associations were observed between
minor alleles of several Fads SNPs, and various fatty
acids, TGs, and D6D and D5D activity in plasma. In
agreement with previous adult studies, a significant
increase in LA and decrease in AA and D5D activity in
plasma were associated with minor alleles in the Fads
cluster. Moreover, the associations observed were highly
significant, which can be attributed to the lack of con-
founding factors masking the effects of genetic variabil-
ity on the phenotype. Further research is necessary to
elucidate the full impact of these genetic effects, and
recent evidence suggests studying younger cohorts will
provide additional insight.
Two genome-wide association studies (GWAS) have
recently confirmed the importance of Fads genes on
lipid metabolism and quantitative traits associated with
disease. Tanaka et al. conducted a GWAS in 1075 parti-
cipants from the InCHIANTI study in order to identify
gene variants that may explain variability in plasma
PUFA levels [61]. The authors found a significant asso-
ciation between a SNP in Fads1 (rs174537) and plasma
levels of AA that accounted for 18.6% of the variance in
AA levels. Carriers of the minor allele had lower levels
of AA, EDA, and EPA, and higher levels of LA and ALA
in plasma; suggesting a decrease in D5D activity.
Furthermore, these individuals had lower levels of total
cholesterol and low-density lipoproteins, indicating that
this minor allele may favour a plasma lipid profile that
decreases the risk for cardiovascular disease. These find-
ings were subsequently validated by the authors in a
second study cohort [61]. These reproducible findings
suggests that genetic variation in Fads1 may not only
explain differences in plasma lipid profiles between indi-
viduals, but may also influence the risk for cardiovascu-
lar disease. Moreover, such studies may shed further
l i g h to nt h ew i d ed i s p a r i t yi nc o n v e r s i o ne f f i c i e n c yo f
ALA to docosahexaenoic acid (DHA, C22:6 n-3)
observed between individuals, which can range from
< 1% to as much as 10% [3,62-64]. In 2010, Illig et al.
conducted a large GWAS that identified strong relation-
ships between traits associated with the metabolic syn-
drome and CVD, and several genetic variants. Serum
from 1809 adults from a German population study
(KORA) and 422 female adults from a British population
study (TwinsUK) were measured, and the concentra-
tions of 163 metabolic traits were analyzed [65]. The
strongest association observed was between a SNP in
the Fads1 gene (rs174547)a n dt h er a t i oo fp r o d u c t
(phosphatidylcholine diacyl C36:4) to precursor (phos-
phatidylcholine diacyl C36:3) fatty acids in both study
cohorts. The authors demonstrate that considering
metabolites as phenotypic traits, combined with the
power of a GWAS, is an effective approach for the iden-
tification of new candidate SNPs. Furthermore, they
revealed that the use of metabolite concentration ratios
as a surrogate measurement of enzymatic activity
reduced variation and yielded strong statistical associa-
tions with a very high degree of significance. Hence,
future studies wishing to discover new genetic variants
associated with disease risk should consider integrating
genetic and metabolomic approaches in order to identify
more robust associations.
These studies establish the importance of the Fads
genes on the regulation of risk factors associated with
health and disease, and as such, demonstrate the need
for future research that elucidates both the molecular
and physiological impact of polymorphisms in the Fads.
Moreover, the observed influence of genetic variation on
whole-body lipid metabolism positions Fads as intri-
guing candidates for future nutrigenomics research.
Genetic Variation in Fads and Breastfeeding
Interesting evidence suggests that the influence of
genetic variation in Fads on circulating and tissue fatty
acid profiles, which contribute to modifying risk factors
for the development of disease, may have a trans-gen-
erational effect [66-68]. Indeed, previous research has
focused on analyzing these effects within an individual
(i.e. a single generation); however, recent studies have
demonstrated that the dietary habits of gestating and/or
lactating mothers may also impact their offspring.
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Page 9 of 14Table 2 Single nucleotide polymorphisms (SNPs) in the Stearoyl-CoA desaturase (Scd-1) gene in four ethnic
populations
CEU CHB JPT YRI
rs2060792 rs2060792 rs2060792
rs7088953 rs7088953
rs17669878 rs17669878 rs17669878 rs17669878
rs11190478 rs11190478 rs11190478 rs11190478
rs735877 rs735877 rs735877 rs735877
rs11599710 rs11599710 rs11599710 rs11599710
rs670213 rs670213 rs670213 rs670213
rs640773 rs640773 rs640773
rs639060 rs639060 rs639060
rs1502593 rs1502593 rs1502593 rs1502593
rs612472 rs612472 rs612472
rs529271 rs529271 rs529271
rs522951 rs522951 rs522951 rs522951
rs681278 rs681278 rs681278
rs11190480 rs11190480 rs11190480 rs11190480
rs11190483 rs11190483 rs11190483
rs7904902
rs3870747 rs3870747 rs3870747 rs3870747
rs3071 rs3071 rs3071
rs3829160 rs3829160 rs3829160
rs3793766 rs3793766 rs3793766 rs3793766
rs12247426
rs3793767 rs3793767 rs3793767 rs3793767
rs3793768 rs3793768 rs3793768 rs3793768
rs2234970 rs2234970 rs2234970 rs2234970
rs599961 rs599961 rs599961
rs10883463
rs3978768 rs3978768 rs3978768
rs11557927 rs11557927 rs11557927 rs11557927
rs10883465 rs10883465 rs10883465 rs10883465
rs7849 rs7849 rs7849 rs7849
rs560792 rs560792 rs560792
rs508384 rs508384 rs508384 rs508384
rs539480 rs539480
rs1393491 rs1393491 rs1393491 rs1393491
rs1393492 rs1393492 rs1393492 rs1393492
rs575338
rs490726 rs490726 rs490726
rs11190488
rs569184
rs569910 rs569910 rs569910 rs569910
rs570844 rs570844 rs570844
rs608622 rs608622 rs608622
rs17113027
This table highlights the ethnic differences in Scd-1 gene variation, using data from the International HapMap Project database (HapMap Data Rel/24phaseII
Nov08, on NCBI B36 assembly, dbSNP b126). Data from the 4 populations was extracted: 1) CEU: CEPH- Utah residents with European ancestry, 2) CHB: Han
Chinese in Beijing, China, 3) JPT: Japanese in Tokyo, Japan, and 4) YRI: Yoruba in Ibadan, Nigeria. Tag SNPs (tSNPs; in bold font) were consistently selected with
Haploview software V4.1 using a minor allele frequency (MAF) > 5% and r
2≥0.8.
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iants in Fads1 and Fads2 may affect lipid composition in
gestating women as well as their breast milk during lac-
tation [68]. This study analyzed six SNPs and the results
demonstrated a direct correlation between genetic var-
iants and lipid composition in plasma phospholipids,
RBC membranes and breast milk. Homozygotic carriers
of the minor allele for the rs174553 SNP had lower AA
and higher LA in plasma phospholipids and RBC mem-
branes, and a lower D6D and D5D product to precursor
ratio at 16 and 36 weeks of gestation. Individuals with
these minor alleles also had significantly lower AA, EPA
and docosapentaenoic acid (DPA, C22:5 n-3), but higher
EDA, in breast milk. Since levels of fatty acids in the
embryo and newborn baby are directly associated to
maternal fatty acid levels (via placental transfer during
gestation and breast milk consumption after birth), any
variation in the maternal intake of fatty acids whose
levels in blood and tissue are sensitive to genetic varia-
bility may prove critical for fetal growth and develop-
ment [66]. Along the same avenue of research, Caspi et
al. analyzed the influence of genetic variation in Fads2
on the association between breastfeeding and infant IQ
[66]. Breastfeeding exposes babies to increased concen-
trations of maternal DHA and AA, crucial fatty acids
known to enhance cognitive development. Therefore, it
was hypothesized that breastfeeding may contribute to a
higher IQ after adjustment for multiple confounders,
such as social class, maternal IQ, genotypic effects on
exposure to breastfeeding and genotypic differences in
intrauterine growth. The authors reported that the
Fads2 SNP (rs174575) interacted with breastfeeding to
influence IQ levels in the two cohorts studied: the
Dunedin cohort (1037 Caucasian children from New
Zealand), and the E-risk cohort (2232 British infant
twins). For both cohorts, it was observed that breastfed
children carrying the common C-allele highly benefitted
from breastfeeding, compared to children who were not
fed breast milk. On the other hand, there was no effect
of breastfeeding on IQ in GG homozygotes. These
results further support the notion that the maternal diet
plays a key role in the development of cognitive func-
tion and that, importantly, genetic variation in Fads2
can alter this association. Indeed, the results reveal that
lipid desaturases are critical in the process of cognitive
development and that the interaction between breast-
feeding (i.e. maternal dietary habits) and variation in
these genes could potentially influence and explain the
observed differences in IQ. These findings suggest that
genetic research should not overlook the influence of
environmental factors on heritability.
Expanding on the diet-gene effects observed in preg-
nant mothers, a recent study by Moltó-Puigmartí et al.
analyzed the influence of Fads polymorphisms on the
association between fish intake and DHA levels in
maternal plasma and breast milk [67]. The study cohort
consisted of 309 Dutch pregnant women from the
KOALA Birth Cohort Study. With the use of a food fre-
quency questionnaire, fish and fish oil intake were esti-
mated and associated to plasma and breast milk fatty
acid levels measured during gestation and 1 month post-
partum, respectively. Furthermore, the effects of genetic
v a r i a t i o ni n3S N P si nt h eFads cluster (rs174561,
rs174575, rs3834458) were analyzed in order to study
the relationship between fish oil intake and DHA con-
centrations in plasma and breast milk. The results
showed that the association between genotype and fatty
acid levels in plasma and milk were additive and that
DHA levels increased in plasma and breast milk in
accordance to the number of major alleles. Interestingly,
it was observed that increased fish and fish-oil intake
elevated the concentration of DHA in plasma, irrespec-
tive of genotype; however, in breast milk, DHA concen-
trations only increased in carriers of the major alleles.
These results demonstrate that modifying the transfer of
DHA from mother to child through dietary interven-
tions will vary based on the mother’s genotype. Further
studies are needed to identify the mechanisms by which
genetic variation in the Fads genes modulate the levels
of DHA in breast milk and the eventual impact of this
genetic variation on the offspring.
Future Directions
It is widely recognized that perturbations in lipid meta-
bolism are associated with the development of human
disease. Moreover, the regulation of lipid metabolism is
truly a complex systems biology paradigm that involves
genes and proteins in multiple tissues throughout the
organism. Consequently, it is crucial to analyze the reg-
ulation of these molecules using comprehensive techni-
ques such as GWAS and ‘omics-based research. The
application of ‘omics-based research provides a comple-
mentary and innovative approach to improve our under-
standing of the role of desaturases in human
metabolism, as recently exemplified by Tanaka et al. and
Illig et al. [61,65]. A few studies have demonstrated that
interactions between diet and gene variants mediate the
risk of chronic disease [58,59]. Indeed, the genetic
makeup of an individual may modulate, to an extent,
the association between nutritional intake and clinical
parameters linked to disease. Further research in this
promising avenue of exploration should try to elucidate
the extent to which these interactions influence the
inter-individual difference for disease risk and try to
identify candidate SNPs that may be used as biomarkers
for diagnosis and personalized therapeutic treatment.
Furthermore, given that dietary habits are tightly
linked to disease susceptibility, it is possible that dietary
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dies, especially when one considers that the consump-
tion of specific fatty acids may mask any changes in
desaturase activities that are genetically determined. Sev-
eral of the studies outlined in this review have demon-
strated that differences related to genotype are masked
by the consumption of ALA, EPA and/or DHA [34,58].
Consequently, proper adjustment for nutritional intake
is of paramount importance when examining associa-
tions that will eventually provide relevant data for the
implementation of dietary interventions that aim at pre-
venting and managing disease.
The study by Shiwaku and colleagues has further rein-
forced the complex relationship between genes and diet
by demonstrating that ethnicity is another important
covariate to consider in gene-association studies using
multi-ethnic populations. This issue may be mute when
establishing cohorts from isolated populations; however,
this becomes extremely relevant when establishing
cohorts from multi-ethnic urban centres. Ethnicity can
be considered a combination of lifestyle, diet, and gene
differences; however, these important factors are often
overlooked in studies involving multi-ethnic populations.
The significant impact of lifestyle on genetic diversity
was recently illustrated by Novembre et al, who reported
that individuals from across Europe can be geographi-
cally clustered using 500,000 SNPs [69]. While this may
not apply to any one SNP in particular, it clearly rein-
forces the important interactions between lifestyle and
genes (i.e. lifestyle genomics) within a population. In
addition, it is difficult to assess the influence of immi-
gration in study populations, which may modify the
association results. Novembre et al. suggested that an
individual’s genetic make-up can be used to infer their
geographic origin [69]. Therefore one can ask, for exam-
ple, at what point does a Caucasian European who has
immigrated to North America become a Caucasian
American at the genetic level? It is entirely possible that
immigrants never fully adapt genetically to their new
environmental surroundings, meaning this is a consider-
able challenge to overcome in order to identify reprodu-
cible gene variants that modify disease risk. To further
reinforce this notion, we used the HapMap database to
extract all SNPs located in a region containing Scd-1 ±
10 kb from the four ethnic groups: 1) CEU - Utah resi-
dents with European ancestry, 2) CHB - Han Chinese
from Beijing China, 3) JPT - Japanese from Tokyo
Japan, and 4) YRI - Yoruba from Ibadan Nigeria (Table
2). It is immediately apparent that the frequency of
common variants differs between the populations. The
CHB and JPT populations are in close proximity from a
geographic perspective, and this is reflected by their
highly similar genetic makeup when compared to the
other two populations. While the differences illustrated
with this example may seem intuitive, it reinforces that
SNPs that are associated with a particular trait in one
population may not be relevant in other populations
simply because they occur only infrequently. Therefore,
considerable effort to homogenize a study cohort must
be taken prior to performing association studies in
order to account for potential lifestyle and ethnic
confounders.
Conclusion
Evidence now exists demonstrating that genetic varia-
tion in Scd-1, Fads1,a n dFads2 can modify desaturase
activity. Initial studies support the notion that genetic
v a r i a t i o ni nt h e s eg e n e sa f f e c t st h eo n s e ta n dd e v e l o p -
ment of various diseases characterized by perturbations
in lipid metabolism. Furthermore, studies that analyze
the interactions between genes and diet have begun to
highlight the influence that maternal dietary habits may
have on their offspring’s growth and development, and
long-term disease risk factors. Therefore, a nutrige-
nomics approach will prove beneficial for unravelling
the interactions between diet and desaturase genes in
ethnically distinct populations. Such research will contri-
bute to the development of tailored dietary strategies for
the prevention and control of disease.
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